June 11, 2025 — MorningStar Laboratories, LLC, a developer of precision diagnostic tests that address unmet clinical needs, has announced its SmartVascular Dx (SVDx) test (formally known as the PULS Cardiac test), designed to transform the early detection and management of vascular health, empowering healthcare providers to implement proactive strategies that significantly enhance patient outcomes.
The SVDx test leverages state-of-the-art technology to provide comprehensive insights into a patient’s vascular health, allowing for earlier intervention and a more personalized care plan. By identifying at-risk individuals through advanced biomarkers, healthcare professionals can initiate preventative measures before critical health issues arise.
“Today marks a significant advancement in how we approach vascular and inflammatory health,” said Lawrence Dentice, President, Chief Commercial Officer & Director, MorningStar Laboratories. “The SmartVascular Dx test is not just a diagnostic tool; it’s a powerful resource for clinicians aimed at redefining our response to vascular risk. We believe early detection and tailored treatment can save lives.”
Clinical Efficacy
The SmartVascular Dx test combines seven protein biomarkers with four clinical factors, demonstrating a high accuracy rate in identifying potential arterial injury due to inflammation. This enhances early detection capabilities, empowering healthcare providers to intervene sooner and improve patient outcomes. It has already been demonstrated in over 200,000 tests.
Recent Developments
MorningStar Laboratories (MSL) has secured licensure in New York State, a recognition of its adherence to stringent laboratory standards. This achievement further affirms the quality and reliability of the SmartVascular Dx test, making it a trusted resource for healthcare professionals.
Physicians can contact MorningStar Laboratories to establish new accounts and integrate the SVDx test into their patient care protocols. By adopting this advanced diagnostic tool, healthcare providers can enhance preventive care strategies and better manage vascular health risks for their patients.
For more information about the test and partnership opportunities, please visit us at https://mslinc.com.
November 03, 2026 
